News

Investor's Business Daily on MSN4h
The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'
Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...
Sarepta drops as report suggests FDA needs new trials for Elevidys
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results
Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.